Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | UBE2N | P61088 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717967 | 0.92 | SLC6A9 (0.35) | GCGKMT2AMEN1GCGRSLC6A9 | |
| SCHEMBL716518 | 0.88 | ALDH1A1 (0.40) | GCGKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL718677 | 0.83 | GCG (0.34) | GCGNTSR1 | |
| SCHEMBL718007 | 0.83 | MAPT (0.38) | KMT2AMEN1ALDH1A1MAPK1CTSS | |
| SCHEMBL2669797 | 0.81 | SLC6A9 (0.42) | GCGKMT2AMEN1GCGRSLC6A9 | |
| SCHEMBL3403967 | 0.80 | MEN1 (0.39) | GCGKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL722931 | 0.79 | NTSR1 (0.33) | GCGKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL720391 | 0.79 | GCG (0.40) | GCGKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL718170 | 0.78 | GCG (0.33) | GCGKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL3399863 | 0.78 | KMT2A (0.38) | GCGKMT2AMEN1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885KMT2A 1298/4885MEN1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.